Filter by Cateogory
KLK1 Mechanism of Action
Genetically modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)
2018
Marina Devetzi, Maria Goulielmaki, Nicolas Khoury, Demetrios A. Spandidos, Georgia Sotiropoulou, Ioannis Christodoulou, and Vassilis Zoumpourlis
Stroke and Stroke Recurrences
Human Tissue Kallikrein in treatment in the treatment of acute ischemic stroke
2019
Michelle Alexander-Curtis, Rick Pauls, Julie Chao, John J Volpi, Philip M Bath, and Todd A. Verdoorn
Kidney Diseases
Open-label study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Patients with Diabetes and Chronic Kidney Disease
2020
Thomas Marbury, Harry Alcorn, George Bakris, Maria Isabel Bermudez, Rajiv Agarwal, Charles Herzog, Glenn Chertow, George Canas
KLK1 Mechanism of Action
Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium
2007
Jane A. Mitchell Ferhana Ali Lucy Bailey Laura Moreno Louise S. Harrington
KLK1 Mechanism of Action
Mechanisms of Disease: the tissue kallikrein–kinin system in hypertension and vascular remodeling
2007
Paolo Madeddu , Costanza Emanueli, Samir El-Dahr
KLK1 Mechanism of Action
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing
2010
Julie Chao, Bo Shen, Lin Gao, Chun-Fang Xia , Grant Bledsoe, and Lee Chao1
1 Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA
Stroke and Stroke Recurrences
Human urinary kallindinogenase (KLK1) therapy for acute ischemic stroke: Clinical efficacy and risk factors
2019
Si‐Qia Chen, Dong‐Yang Mao, Dun‐Can Wei, Wen‐Zhen He
Stroke and Stroke Recurrences
Efficacy and safety of human urinary kallidinogenase (KLK1) for acute ischemic stroke: a meta-analysis
2020
Yuanxiang Huang, Binglei Wang, Yue Zhang, Peize Wang, Xiangjian Zhang
Stroke and Stroke Recurrences
Human Urinary Kallidinogenase decreases recurrent risk and promotes good recovery
2018
Dong Han, Xin Chen, Dongmei Li, Shuang Liu, Yi Lyu, and Juan Feng
Kidney Diseases
Exogenous kallikrein protects against diabetic nephropathy
2016
Wenjuan Liu 11, Yeping Yang 11, Yemei Liu 11, Xiaolan Lu, Shizhe Guo, Meng Wu, Meng Wang, Linling Yan, Qinghua Wang, Xiaolong Zhao, Xian Tong, Ji Hu, Yiming Li, Renming Hu, Robert C. Stanton, Zhaoyun Zhang
Kidney Diseases
The Effect of Pancreatic Kininogenase (KLK1) Combined with Valsartan for the Treatment of Early DN
2013
Chin J Lab Diagn, December 2013, Vol 17, No. 12
Kidney Diseases
Clinical Efficacy of Pancreatic Kininogenase (KLK1) in the Treatment of Diabetic Nephropathy: A Systematic Evaluation
2014
Hainan Medical Journal, 2014-01
Stroke and Stroke Recurrences
Preclinical KLK1 Mechanism for AIS
2014
Human Urinary Kallidinogenase Promotes Angiogenesis and Cerebral Perfusion in Experimental Stroke
Stroke and Stroke Recurrences
DM199/KLK1 for AIS Review Paper
2019
Human tissue kallikrein in the treatment of acute ischemic stroke
Stroke and Stroke Recurrences
Urinary KLK1 after thrombolytic (tPA) treatment for acute cerebral infarction
2015
Department of Neurology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin, China
Kidney Diseases
The kallikrein–kinin system in diabetic kidney disease
2017
Liu, Wenjuan; Stanton, Robert C.; Zhang, Zhaoyun
Kidney Diseases
Mechanisms of Disease: the tissue kallikrein–kinin system in hypertension and vascular remodeling
2007
Paolo Madeddu, Costanza Emanueli & Samir El-Dahr